There is no clinical syndrome associated with an overdosage of cromolyn sodium . In several animal species acute toxicity with cromolyn sodium occurs only with very high exposure levels. No deaths occurred at the highest oral doses tested in mice, 8,000 mg/kg (approximately 5,100 and 2,700 times the maximum recommended daily inhalation doses in adults and children, respectively, on a mg/m 2 basis) or in rats, 8,000 mg/kg (approximately 10,000 and 5,400 times the maximum recommended daily inhalation doses in adults and children, respectively, on a mg/m 2 basis).

Q. Do I need to go through all the patient records on the PMR system for the last 6 months and identify any patients who have been prescribed more than 6 short acting bronchodilator inhalers without a corticosteroid inhaler within a 6-month period to meet this criterion?
No. Contractors do not need to have reviewed 6 months of patient records to meet this criterion. On the day of the review the pharmacy must be able to show evidence of the asthma patients, for whom more than 6 short acting bronchodilator inhalers were dispensed without any corticosteroid inhaler within a 6-month period, that have been referred to an appropriate health care professional for an asthma review. There must, therefore, be a process in place, to identify these asthma patients. This process can be incorporated into daily practice (PSNC has suggested a process for referring patients for an asthma review).